25-OH-VitD3、BGP和Apelin-13与T2DM肥胖患者阿格列汀及利拉鲁肽疗效的关系  

Relationship between 25-OH-VITD3,BGP,apelin-13 and efficacy of alagliptin and liraglutide in obese patients with T2DM

作　　者：马朝朋 王晓妍[1] 尹超[1] 马竞轩 宋彦伟 郭淑芹[1] 王君[1] MA Chaopeng;WANG Xiaoyan;YIN Chao;MA Jingxuan;SONG Yanwei;GUO Shuqin;WANG Jun(Department of Endocrinology,Baoding First Central Hospital,Baoding,Heibei,China,071000)

机构地区：[1]保定市第一中心医院内分泌三科,河北保定071000

出　　处：《分子诊断与治疗杂志》2022年第9期1554-1557,共4页Journal of Molecular Diagnostics and Therapy

基　　金：保定市科技计划项目(1951ZF051)。

摘　　要：目的观察2型糖尿病(T2DM)肥胖患者阿格列汀及利拉鲁肽治疗中血清25羟基维生素D3(25-OH-VitD3)、骨钙素(BGP)、爱帕琳肽-13(Apelin-13)水平,并探讨三种血清与疗效的关系。方法选取2019年11月至2020年11月在保定市第一中心医院接受阿格列汀及利拉鲁肽治疗的116例T2DM肥胖患者,均治疗24周,并按疗效分成有效组和无效组。检测患者的血清25-OH-VitD3、BGP、Apelin-13水平,收集患者的临床资料,并单因素和多元Logistic回归分析25-OH-VitD3、BGP、Apelin-13水平与T2DM肥胖患者阿格列汀及利拉鲁肽疗效的关系。结果116例T2DM肥胖患者中,84例(72.41%)治疗有效,32例(27.59%)治疗无效;经Logistic回归分析显示,血清25-OH-VitD3、BGP、Apelin-13水平是T2DM肥胖患者阿格列汀及利拉鲁肽治疗无效的影响因素(P<0.05);受试者工作特征(ROC)曲线显示,三者联合检测的曲线下面积(AUC)的预测价值最佳。结论血清25-OH-VitD3、BGP、Apelin-13水平和T2DM肥胖患者阿格列汀及利拉鲁肽疗效密切相关,且三者联合检测可作为患者治疗效果的预测指标。Objective To observe the serum levels of 25 hydroxyvitamin D3(25-OH-vitD3),osteocalcin(BGP)and apelin-13(apelin-13)in obese type 2 diabetes mellitus(T2DM)patients treated with alagliptin and liraglutide,and to explore the relationship between the three serum levels and the curative effect.Methods A total of 116 T2DM obese patients who received alagliptin and liraglutide in Baoding First Central Hospital from November 2019 to November 2020 were selected and treated for 24 weeks.They were divided into the effective group and the ineffective group according to the efficacy.Serum 25-OH-VITD3,BGP,apelin-13 levels were detected,clinical data of patients were collected,and the relationship between 25-OH-VITD3,BGP,apelin-13 levels and the efficacy of alagliptin and liraglutide in T2DM obese patients was analyzed by univariate and multivariate logistic regression analysis.Results Among the 116 obese patients with T2DM,84cases(72.41%)were treated effectively,while 32 cases(27.59%)were ineffective.Logistic regression analysis showed that serum levels of 25-OH-VITD3,BGP and apelin-13 were the influencing factors of ineffective treatment of alagliptin and liraglutide in T2DM obesity,and the difference was statistically significant(P<0.05).The receiver operating characteristic(ROC)curve showed that the area under the curve(AUC)combined with the three measures had the best predictive value.Conclusion Serum 25-OH-VITD3,BGP and apelin-13 levels are closely correlated with the therapeutic effect of alagliptin and liraglutide in obese patients with T2DM,and the combined detection of the three can be used as a predictor of the treatment effect of patients.

关 键 词：25羟基维生素D3 骨钙素 爱帕琳肽-13 2型糖尿病合并肥胖 阿格列汀 利拉鲁肽 

分 类 号：R587.1[医药卫生—内分泌]